Tafamidis Drug Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Tafamidis Drug Market Trends and Insights

Rising Diagnosis Of ATTR-CM Through Advanced Cardiac Imaging

Non-invasive diagnosis using 99mTc-PYP and related bone scintigraphy has changed the way ATTR-CM is found in the tafamidis drug market. The 2025 epidemiology review showed rising incidence and prevalence across the United States and Europe, with especially strong growth among men older than 65 in countries with established scintigraphy use. U.S. incidence reached 44.3 per 100,000 person-years, which reflected better detection rather than a sudden change in underlying disease burden. This matters for the tafamidis drug market because imaging identifies more patients before advanced functional decline, which supports earlier treatment start. Earlier initiation tends to capture more NYHA Class I and II patients, and this group has been the clearest clinical fit for tafamidis use. The result is that the tafamidis drug market gains both a larger diagnosed base and a longer treatment window per patient.

Aging Patient Pool And Higher ATTR-CM Prevalence In Older Populations

The tafamidis drug market is closely tied to aging because wild-type ATTR-CM is concentrated in older adults^{[1]Source: Yun S. et al., “International Prevalence Of Transthyretin Amyloid Cardiomyopathy In High-Risk Patients With Heart Failure And Preserved Or Mildly Reduced Ejection Fraction,” Amyloid Journal of Protein Folding Disorders, openaccess.sgul.ac.uk}. A 2024 international study showed that prevalence in high-risk HFpEF populations above age 85 reached or exceeded 40%, which confirms how strongly age drives case finding. Population aging across North America, Western Europe, and East Asia is therefore enlarging the diagnosis pool and sustaining demand for treatment. Japan stands out with documented ATTR-CM prevalence of 100 per million per year, and that disease burden has not yet been fully matched by prescription volumes because earlier eligibility rules were stricter. The 2025 revision of Japan’s Heart Failure Clinical Guidelines gave tafamidis a Class I, Evidence Level A recommendation for NYHA Class I and II ATTR-CM patients, which now supports wider use. This guideline shift should keep the tafamidis drug market on a firmer growth path in Japan over the medium term.

Broader Cardiology Adoption Of Disease-Modifying Therapies

Broader use by cardiologists is widening the prescribing base for the tafamidis drug market. HFpEF accounts for 50% of global heart failure cases, and ATTR-CM has been identified in 18% of high-risk HFpEF subgroups compared with 3% in unselected cohorts. This has pushed cardiologists to screen more routinely in patients with carpal tunnel history, bicuspid aortic stenosis, and unexplained concentric hypertrophy. The 2025 ACC concise clinical guidance placed TTR stabilizer therapy within standard management for confirmed ATTR-CM, which moved tafamidis further into mainstream cardiology protocols. Historical orphan-drug and breakthrough pathways also helped speed regulatory progress, while ongoing post-marketing monitoring continues to shape how manufacturers support distribution and access. As the referral barrier between general cardiology and specialist centers falls, the tafamidis drug market is reaching more patients without relying only on rare disease centers.

Earlier Referral From Heart Failure Clinics To Amyloidosis Centers

Earlier referral from heart failure clinics is shortening the path to treatment in the tafamidis drug market. Dedicated amyloidosis clinics now combine echocardiography, nuclear imaging, and genetic testing in a single care pathway, which reduces delays that used to occur in sequential workups. The Japanese claims study showed shorter diagnostic timelines when patients were managed at specialist centers with formal imaging protocols. Heart failure clinics are now acting as practical referral hubs for ATTR-CM cases that once might have remained misclassified in broader HFpEF populations. Patients often arrive at amyloidosis centers with preliminary imaging already completed, which allows a faster move from suspicion to prescription. That compression in time to therapy is supporting annual prescription growth in the tafamidis drug market, especially in tertiary hospitals and academic centers. 

High Annual Therapy Cost And Payer Prior Authorization Requirements

High cost remains a direct limit on the tafamidis drug market even after recent access improvements. Tafamidis carries a U.S. list price of USD 234,900 per year, which places it among the most expensive cardiovascular therapies. Major payers require diagnosis confirmation, cardiology attestation, and functional assessment before they approve dispensing, and each plan has its own utilization rules. The 2025 Medicare Part D cap reduced patient financial burden, but some Medicare Advantage plans still placed Vyndamax in non-preferred specialty tiers, which kept plan-level friction in place. That means access barriers in the tafamidis drug market now come less from direct patient affordability and more from administrative delay, formulary placement, and documentation requirements. Appeals channels still exist for medically necessary treatment, but the prescriber burden remains significant and slows faster uptake.

Competitive Pressure From RNA-Silencing And Next-Generation Therapies

The tafamidis drug market is facing stronger competitive pressure from therapies that reduce TTR production rather than stabilize the protein. Alnylam’s Amvuttra received FDA approval for ATTR-CM in March 2025 and introduced a subcutaneous RNA interference therapy dosed every 3 months. In HELIOS-B, Amvuttra showed a 28% relative reduction in all-cause mortality and cardiovascular events versus placebo, which strengthened its case in ATTR-CM treatment. This creates a prescriber narrative that upstream TTR suppression may fit advanced disease or high amyloid burden better than stabilization alone. Next-generation RNAi candidates such as nucresiran are also being developed with twice-annual dosing and at least 95% TTR knockdown, which raises the competitive bar further. The pressure is strongest among new-to-therapy patients in the tafamidis drug market, where differentiation by mechanism, dosing frequency, and expected outcomes carries the most weight.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Tafamidis Free Acid Anchors Revenue as Generic Horizon Approaches

Tafamidis free acid held 61.53% of the tafamidis drug market share in 2025, which reflected the commercial strength of Pfizer’s once-daily Vyndamax and related brands in other countries. The single-capsule regimen offered a practical adherence advantage over the older four-capsule tafamidis meglumine presentation. Pfizer’s decision to discontinue Vyndaqel 20 mg in the U.S. by the end of 2025 further concentrated branded revenue around the free acid format. Tafamidis meglumine still retains relevance in markets where the free acid version has not secured local approval or where legacy patient cohorts remain established on older treatment protocols. A 2025 post-approval study in China showed that tafamidis free acid 61 mg delivered safety and efficacy findings consistent with international Phase 3 evidence, which supported confidence in markets absent from the original ATTR-ACT enrollment base^{[2]Springer Nature / Cardiology and Therapy. "Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy." 2025. https://link.springer.com/article/10.1007/s40119-025-00408-6}.

The tafamidis drug market size for generic products is projected to expand at a 18.17% CAGR through 2031, making generic tafamidis the fastest-growing product segment. Indian manufacturers, including Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin, Torrent Pharmaceuticals, Sun Pharmaceutical Industries, and Zydus Lifesciences are building active pharmaceutical ingredient capabilities ahead of the June 2031 U.S. entry date tied to Pfizer’s settlements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla. Growth in this segment is expected to be uneven because some ex-U.S. markets can absorb generic tafamidis earlier under more favorable reimbursement settings, while the U.S. branded market remains protected until mid-2031. The molecule follows established organic chemistry routes, so price erosion after generic entry could be sharper than in rare-disease therapies with more complex manufacturing barriers. That outlook means the tafamidis drug market will likely see branded companies defend value through access execution, channel control, and clinical differentiation rather than formulation alone 

By Application: ATTR-CM Dominates as Screening Expands Into Mainstream Cardiology

ATTR-CM accounted for 67.30% of the tafamidis drug market size in 2025, supported by broader recognition of wild-type disease in older cardiac patients. Non-invasive scintigraphy has made screening more practical in patients with HFpEF, carpal tunnel history, and unexplained ventricular thickening, which keeps ATTR-CM central to demand. The 2025 ACC clinical guidance reinforced tafamidis as a standard option in confirmed ATTR-CM management, which gives this segment a durable treatment anchor. Hereditary transthyretin amyloid polyneuropathy remains the second application segment because tafamidis had an earlier approval history in neuropathy than in cardiac disease across several markets. Familial amyloid polyneuropathy continues as a narrower niche in Portugal, Sweden, and Japan, where endemic TTR variants and long-standing registries sustain targeted use.

The tafamidis drug market size for mixed phenotype ATTR amyloidosis is forecast to expand at a 11.16% CAGR through 2031, making it the fastest-growing application segment. Current clinical literature places 24.5% of symptomatic ATTR patients in the mixed phenotype group, which means both cardiac and neurologic manifestations are present at the same time.. This subset has been underserved because treatment pathways often focused on either pure ATTR-CM or pure ATTR-PN rather than combined disease expression. Tafamidis aligns well with that need because systemic TTR stabilization can address both cardiac and peripheral manifestations within one therapeutic approach. As genetic sequencing and multimodal imaging sharpen phenotyping, the tafamidis drug market should see more newly identified mixed-phenotype patients enter treatment pathways.

By Distribution Channel: Hospital Pharmacies Lead While Specialty Channels Accelerate

Hospital pharmacies represented 46.73% of the tafamidis drug market in 2025 because diagnosis and treatment initiation were concentrated in tertiary hospitals, academic medical centers, and specialized amyloidosis programs. These sites handle the multidisciplinary workflow that typically includes cardiologists, neurologists, genetic counselors, and pharmacists, all of whom support documentation for payer approval. Hospital dispensing also fits renewal requirements because patients can be monitored more closely for hospitalization history, walking ability, and broader functional status. That operational fit keeps hospital pharmacies at the center of first-treatment use in the tafamidis drug market. Retail and online pharmacies still play a role, but most of that demand comes from stable maintenance patients who move out of hospital-based dispensing after treatment routines are established.

Specialty pharmacies are expected to record the fastest growth in the tafamidis drug market, at a 16.23% CAGR through 2031. Payer mandates for high-cost rare-disease drugs are a major reason, since many plans route dispensing through specialty pharmacy networks rather than general retail channels. These pharmacies also provide prior authorization support, adherence outreach, and patient assistance coordination, which directly reduces interruption risk. This channel is likely to become even more important as branded manufacturers prepare to defend retention and service quality in the years approaching generic competition. The others category remains relevant for institutional buyers, managed care direct-dispensing arrangements, and outpatient hospital programs that do not fit standard retail or specialty classifications.

Geography Analysis

North America held 39.37% of the tafamidis drug market share in 2025, making it the largest regional revenue base. The United States drove most of that demand because it has the deepest ATTR-CM diagnostic infrastructure, broad access to 99mTc-PYP scintigraphy, and the highest per-patient therapy spending. The 2025 Medicare Part D redesign improved patient affordability, but plan-level tiering still created friction in some Medicare Advantage settings. Canada and Mexico remain smaller contributors because reimbursement structures and specialist density are less favorable than in the United States. South America, led by Brazil and Argentina, supports demand through rare disease access programs and the presence of hereditary TTR variants in Portuguese-descended populations, which keep both ATTR-PN and ATTR-CM clinically relevant^{[3]Journal of the American Heart Association. "Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States." 2025. https://doi.org/10.1161/jaha.125.047135}.

Europe remains the second-largest geography in the tafamidis drug market, with Germany, the United Kingdom, France, Italy, and Spain forming the core base. The European Commission approval of Beyonttra in February 2025 introduced direct TTR stabilizer competition, which will shape prescribing and pricing decisions more actively through 2031. Tafamidis still benefits from physician familiarity and from reimbursement frameworks that are already established with major health technology assessment bodies. Portugal and Sweden maintain a distinct neuropathy patient base linked to endemic TTR variants, while the rest of Europe offers incremental growth as diagnosis spreads beyond Western European specialist centers.

Asia-Pacific is the fastest-growing region in the tafamidis drug market and is forecast to expand at a 17.63% CAGR over 2026-2031. Japan has the highest documented ATTR-CM prevalence at 100 per million per year, and the 2025 guideline revision is now improving the path to broader Vynmac use in NYHA Class I and II patients. China is strengthening its position as a growth market because post-approval data in Chinese patients supported the safety and efficacy of tafamidis free acid 61 mg. India, Australia, and South Korea should grow from a smaller base as access improves, especially once pricing becomes more compatible with reimbursement expansion. The Middle East and Africa still represent a small share of the tafamidis drug market, with demand centered in GCC countries and broader regional growth dependent on stronger scintigraphy capacity and specialist diagnosis pathways